Human Immunoglobulin E specific for Vespula vulgaris venom allergens (sIgE (Vespula vulgaris))

Human Immunoglobulin E (IgE) antibodies specific for Vespula vulgaris (common wasp) venom allergens are the primary mediators of type I hypersensitivity reactions in sensitized individuals (Hoffman, 2006, PMID: 16785582). These antibodies recognize specific venom proteins, most notably Ves v 1 (phospholipase A1) and Ves v 5 (antigen 5), and bind to high-affinity FcεRI receptors on the surface of mast cells and basophils (Bilò et al., 2005, PMID: 16197464). Upon subsequent exposure to wasp venom, the allergens cross-link the surface-bound IgE, triggering the rapid release of inflammatory mediators like histamine and leukotrienes, which can lead to local swelling or life-threatening anaphylaxis (Sturm et al., 2018, PMID: 29205393). In clinical practice, these IgE antibodies serve as both a diagnostic marker and a therapeutic target. Monoclonal antibodies such as omalizumab can sequester circulating IgE to prevent mast cell activation, while venom immunotherapy (VIT) aims to desensitize the patient by modulating the immune system's production of these antibodies (Eberlein et al., 2012, PMID: 22893556). Monitoring the levels and activity of Vespula-specific IgE is crucial for assessing the risk of severe reactions and the efficacy of desensitization treatments.

Other names

Anti-Vespula vulgaris IgEWasp venom-specific IgEVes v-specific IgEYellow jacket venom-specific IgE

Drugs like omalizumab bind to the Cε3 domain of circulating IgE, preventing its interaction with high-affinity IgE receptors (FcεRI) on mast cells and basophils (National Institutes of Health, DailyMed). Venom immunotherapy (VIT) works by inducing immune tolerance, shifting the response from a Th2-mediated IgE production to a Th1/Treg-mediated production of IgG4 antibodies, which act as blocking antibodies (Sturm et al., 2018, PMID: 29205393).